427 related articles for article (PubMed ID: 34715057)
41. Advances in the treatment of Kawasaki disease.
Dominguez SR; Anderson MS
Curr Opin Pediatr; 2013 Feb; 25(1):103-9. PubMed ID: 23283289
[TBL] [Abstract][Full Text] [Related]
42. Nomogram to predict risk of resistance to intravenous immunoglobulin in children hospitalized with Kawasaki disease in Eastern China.
Huang H; Jiang J; Shi X; Qin J; Dong J; Xu L; Huang C; Liu Y; Zheng Y; Hou M; Shen Q; Zeng B; Qian G; Yang F; Lv H
Ann Med; 2022 Dec; 54(1):442-453. PubMed ID: 35099338
[TBL] [Abstract][Full Text] [Related]
43. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
Iio K; Morikawa Y; Miyata K; Kaneko T; Misawa M; Yamagishi H; Miura M
J Pediatr; 2022 Jan; 240():158-163.e4. PubMed ID: 34461064
[TBL] [Abstract][Full Text] [Related]
44. [Retrospective analysis of infliximab in the treatment of Kawasaki disease].
Xie LP; Zhao L; Chu C; He L; Liang XC; Sun SN; Zhao QM; Wang F; Cao YY; Lin YX; Zeng ZQ; Wu L; Huang GY; Liu F
Zhonghua Er Ke Za Zhi; 2022 Jan; 60(1):14-19. PubMed ID: 34986617
[No Abstract] [Full Text] [Related]
45. Sivelestat sodium hydrate treatment for refractory Kawasaki disease.
Ebata R; Yasukawa K; Nagai K; Saito Y; Higashi K; Homma J; Takada N; Takechi F; Saito N; Kobayashi H; Okunushi K; Hamada H; Kohno Y; Hanaoka H; Shimojo N
Pediatr Int; 2019 May; 61(5):438-443. PubMed ID: 30916859
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T; Saji T; Otani T; Takeuchi K; Nakamura T; Arakawa H; Kato T; Hara T; Hamaoka K; Ogawa S; Miura M; Nomura Y; Fuse S; Ichida F; Seki M; Fukazawa R; Ogawa C; Furuno K; Tokunaga H; Takatsuki S; Hara S; Morikawa A;
Lancet; 2012 Apr; 379(9826):1613-20. PubMed ID: 22405251
[TBL] [Abstract][Full Text] [Related]
47. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
[TBL] [Abstract][Full Text] [Related]
48. The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease.
Ebato T; Ogata S; Ogihara Y; Fujimoto M; Kitagawa A; Takanashi M; Ishii M
J Pediatr; 2017 Dec; 191():140-144. PubMed ID: 29173297
[TBL] [Abstract][Full Text] [Related]
49. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group.
Burns JC; Capparelli EV; Brown JA; Newburger JW; Glode MP
Pediatr Infect Dis J; 1998 Dec; 17(12):1144-8. PubMed ID: 9877364
[TBL] [Abstract][Full Text] [Related]
50. [Anti TNF-α (infliximab) treatment for intravenous immunoglobulin (IVIG) resistance patients with acute Kawasaki disease the effects of anticytokine therapy].
Saji T; Takatsuki S; Kobayashi T
Nihon Rinsho; 2014 Sep; 72(9):1641-9. PubMed ID: 25518416
[TBL] [Abstract][Full Text] [Related]
51. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
Lee TJ; Kim KH; Chun JK; Kim DS
Yonsei Med J; 2008 Oct; 49(5):714-8. PubMed ID: 18972590
[TBL] [Abstract][Full Text] [Related]
52. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
Kobayashi T; Motoya S; Nakamura S; Yamamoto T; Nagahori M; Tanaka S; Hisamatsu T; Hirai F; Nakase H; Watanabe K; Matsumoto T; Tanaka M; Abe T; Suzuki Y; Watanabe M; Hibi T;
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):429-437. PubMed ID: 33887262
[TBL] [Abstract][Full Text] [Related]
53. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
Li W; He X; Zhang L; Wang Z; Wang Y; Lin H; Yuan J; Xie X; Qin Y; Huang P
Cardiovasc Ther; 2021; 2021():6660407. PubMed ID: 34239607
[TBL] [Abstract][Full Text] [Related]
54. Real-world Safety and Effectiveness of Infliximab in Pediatric Patients With Acute Kawasaki Disease: A Postmarketing Surveillance in Japan (SAKURA Study).
Miura M; Kobayashi T; Igarashi T; Hamada H; Iwata N; Sasaki Y; Matsukawa M; Sato N; Kubo H; Takei S
Pediatr Infect Dis J; 2020 Jan; 39(1):41-47. PubMed ID: 31815838
[TBL] [Abstract][Full Text] [Related]
55. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
Inoue Y; Okada Y; Shinohara M; Kobayashi T; Kobayashi T; Tomomasa T; Takeuchi K; Morikawa A
J Pediatr; 2006 Sep; 149(3):336-341. PubMed ID: 16939743
[TBL] [Abstract][Full Text] [Related]
56. A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment.
Johnson SC; Williams DC; Brinton D; Chew M; Simpson A; Andrews AL
Hosp Pediatr; 2021 Jan; 11(1):88-93. PubMed ID: 33293266
[TBL] [Abstract][Full Text] [Related]
57. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
Chen S; Dong Y; Kiuchi MG; Wang J; Li R; Ling Z; Zhou T; Wang Z; Martinek M; Pürerfellner H; Liu S; Krucoff MW
JAMA Pediatr; 2016 Dec; 170(12):1156-1163. PubMed ID: 27749951
[TBL] [Abstract][Full Text] [Related]
58. Intravenous immunoglobulin for the treatment of childhood encephalitis.
Iro MA; Martin NG; Absoud M; Pollard AJ
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD011367. PubMed ID: 28967695
[TBL] [Abstract][Full Text] [Related]
59. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
Burns JC; Song Y; Bujold M; Shimizu C; Kanegaye JT; Tremoulet AH; Franco A
Clin Exp Immunol; 2013 Dec; 174(3):337-44. PubMed ID: 23901839
[TBL] [Abstract][Full Text] [Related]
60. Ulinastatin therapy in kawasaki disease.
Iwashima S; Seguchi M; Matubayashi T; Ohzeki T
Clin Drug Investig; 2007; 27(10):691-6. PubMed ID: 17803344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
